Vicuron is a biopharmaceutical company focused on the development of novel infection fighters for both hospital-based and community-acquired infections.
Through the transaction, Pfizer has acquired two new product candidates currently under review at the FDA. These are anidulafungin for fungal infections and dalbavancin for Gram-positive infections. The addition of these product candidates broadens Pfizer’s presence in infection fighting drugs.
The completion of the acquisition of Vicuron that was first announced in June of this year is some better news for Pfizer that recently was forced to announce that its new drug application for the osteoporosis drug Oporia has been rejected by the FDA. Oporia had been expected to be a big selling drug for Pfizer with sales projected to be as much as $1 billion per year.